| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7aad04afa7d836bbeb80a73964f79b64 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-141
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2510-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-531 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-90
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-713
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1135
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0688
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0693 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-90
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-713
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10 |
| filingDate |
2022-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cec1133eb655e0ea4492911239891d4b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bfb25d96a88b193446471e294a87eda9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6d7920b5f46de17e4aa753b5ca99b74d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_25febb8a7a541a68fd896f5f1e172dce
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f0a42aaad76f33eafee246dee779fa16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f77d6044983a45598dcc02eccaea44b7 |
| publicationDate |
2022-07-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-114763548-A |
| titleOfInvention |
Methods and applications of CDH15 to overcome drug resistance in the treatment of lung cancer |
| abstract |
The invention belongs to the field of biomedicine, and relates to the application of CDH15 silencing for alleviating the resistance of lung cancer to EGFR-TKIs. The invention provides the application of CDH15, a molecular marker for overcoming the resistance of EGFR-TKIs, in the treatment of lung cancer. The invention realizes that the expression of CDH15 in lung cancer drug-resistant cell lines is increased, and silencing CDH15 can partially overcome the drug resistance of lung cancer EGFR-TKI; the invention provides a new auxiliary method for the treatment of EGFR-TKI drug resistance, And enriches the therapeutic direction of CDH15 in diseases; the present invention provides a potential research direction for CDH15 to overcome EGFR-TKI resistance of lung cancer. |
| priorityDate |
2022-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |